Request Demo

Last update 12 Aug 2025

Meropenem

Last update 12 Aug 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Belopenem, Mepem, Meropen

+ [23]

Target

PBPs

Action

inhibitors

Mechanism

PBPs inhibitors(Bacterial penicillin-binding protein inhibitors)

Therapeutic Areas

Infectious DiseasesNervous System DiseasesDigestive System Disorders+ [8]

Active Indication

Complicated intra-abdominal infectionMeningitis, Bacterial(non-specific) purulent meningitis+ [27]

Inactive Indication

CellulitisPneumonia, Ventilator-Associated

Originator Organization

Sumitomo Pharma Co., Ltd.

Active Organization

Sumitomo Pharma Co., Ltd.

Pfizer Australia Pty Ltd.

B. Braun Medical, Inc.

+ [3]

Inactive Organization

Melinta Therapeutics, Inc.

Matinas BioPharma Holdings, Inc.

Pfizer Inc.

+ [1]

License Organization

Cardinal Health (Shanghai) Pharmaceutical Co., Ltd.

AstraZeneca PLC

Pfizer Inc.

+ [1]

Drug Highest PhaseApproved

First Approval Date

Japan (30 Jun 1995),

AdnexitisArthritisCholangitis+ [16]

RegulationOrphan Drug (United States)

Structure/Sequence

Molecular FormulaC17H27N3O6S

InChIKeyWCDAAZJSDNCCFU-NACOAMSHSA-N

CAS Registry119478-56-7

174

Clinical Trials associated with Meropenem

NCT07096310

/ Not yet recruitingPhase 1/2IIT

Comparison Between Carbapenems and Noncarbapenem Broad Spectrum Beta-lactam Antibiotics as Initial Antibiotic Therapy Against Sepsis in Burn Patients: A Prospective Study

The aim of this work is to evaluate the efficacy associated with Meropenem(example of carbapenems) as initial therapy for sepsis in burn patients compared with Pipracillin/Tazobactam (example of non carbapenem beta lactam antibiotics).

Start Date01 Aug 2025

Sponsor / Collaborator

Ain Shams University

NCT06184659

/ RecruitingPhase 4IIT

Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis (EMPRESS) Trial

The EMPRESS trial aims to test the two most commonly used antibiotics (meropenem and piperacillin/tazobactam) among intensive care patients with sepsis (blood poisoning), as the safety of these two drugs is unclear in this group of patients.

Start Date26 Jun 2025

Sponsor / Collaborator-

CTIS2024-516360-29-00

/ RecruitingPhase 2

A Multi-Center, Open-Label, Single-Arm, Phase 2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vabomere (meropenem-vaborbactam) in the Treatment of Children with Complicated Urinary Tract Infection, Including Acute Pyelonephritis - ML-VAB-201-3248-2

Start Date03 Jun 2025

Sponsor / Collaborator

Rempex Pharmaceuticals, Inc.

100 Clinical Results associated with Meropenem

100 Translational Medicine associated with Meropenem

100 Patents (Medical) associated with Meropenem

25,718

Literatures (Medical) associated with Meropenem

01 Jan 2026·TALANTA

A fluorescent sensor based on nitrogen-doped graphene quantum dots and molecularly imprinted polymers for selective and sensitive detection of meropenem in environmental and clinical matrices

Article

Author: Almalki, Atiah H ; Ramzy, Sherif ; Alaqel, Saleh I ; Alzhrani, Rami M ; Alosaimi, Manal E ; Abdelazim, Ahmed H ; Althobaiti, Yusuf S ; Alnemari, Reem M ; Abduljabbar, Maram H ; Serag, Ahmed

Meropenem, a broad-spectrum carbapenem antibiotic, is widely used in the treatment of severe bacterial infections. However, the accurate determination of meropenem in complex biological and environmental matrices remains a significant analytical challenge. In this study, we report the development of a highly sensitive and selective fluorescence sensor for the determination of meropenem using nitrogen-doped graphene quantum dots capped with a surface molecular imprinting polymer (N-GQDs@MIP). Characterization and optical properties of the N-GQDs@MIP nanocomposite were thoroughly investigated using various analytical techniques. Upon excitation at 365 nm, the sensor exhibited strong fluorescence emission at 450 nm which quenched upon meropenem binding. Mechanistic studies revealed a static quenching process driven by strong host-guest interactions between meropenem and the imprinted polymer recognition sites, as confirmed by Stern-Volmer analysis and thermodynamic calculations. Density functional theory calculations also revealed specific molecular interactions between meropenem and the N-GQDs@MIP. Central composite design optimization was employed to systematically investigate the effect of key experimental parameters, such as pH, reaction time, and N-GQDs@MIP concentration, on the sensor's performance. A significant quadratic regression model was obtained, with a high coefficient of determination (R² = 0.956) and excellent predictive capability that was further employed to maximize the sensor's sensitivity. Validation of the analytical method demonstrated a wide linear range of 25-1500 ng/mL, a low limit of detection of 7.42 ng/mL, and excellent selectivity against structurally similar antibiotics as well as good stability and reusability. The developed N-GQDs@MIP sensor was successfully applied to the determination of meropenem in pharmaceutical formulations, spiked human serum, urine, and environmental water samples with satisfactory recoveries and precision. Hence, this facile and robust fluorescence sensor offers a promising analytical platform for the sensitive, selective, and reliable quantification of meropenem in various clinical and environmental applications posing the current approach as a valuable alternative to existing analytical methods.

31 Dec 2025·Emerging Microbes & Infections

The emergence of highly resistant and hypervirulent Escherichia coli ST405 clone in a tertiary hospital over 8 years

Article

Author: Sun, Zhifei ; Zhao, Shuping ; Du, Hong ; Chen, Liang ; Jiang, Meijie ; Wang, Min ; Wang, Xinying ; Zhang, Zhijun ; Zhu, Jie ; Feng, Qiang

The emergence of carbapenem-resistant Escherichia coli (CREC) poses crucial challenges in clinical management, requiring continuous monitoring to inform control and treatment strategies. This study aimed to investigate the genomic and epidemiological characteristics of CREC isolates obtained from a tertiary hospital in China between 2015 and 2022. Next-generation sequencing was used for genomic profiling, and clinical data from patients were integrated into the analysis. ST405 (21.2%), ST167 (20.3%) and ST410 (15.9%) were the most prevalent of the 30 distinct sequence types (STs) identified among the 113 unique CREC isolates. Infections caused by the ST405 CREC clone and severe underlying diseases were associated with higher in-hospital mortality rates, particularly in patients aged ≥65 years. Furthermore, the ST405 clone exhibited a greater number of virulence and resistance genes than non-ST405 CREC clones. The virulence gene eaeX and resistance genes mph(E) and msr(E) were exclusively found in ST405 clones, while other virulence genes (agn43, ipad and malX) and resistance genes (armA, catB3 and arr-3) were more prevalent in this clones. Additionally, ST405 showed higher minimum inhibitory concentrations for both meropenem and imipenem and showed superior growth under the meropenem challenge. Galleria mellonella virulence assays revealed that the ST405 CREC clone was more virulent than other predominant CREC STs. Our findings underscore the clinical threat posed by the ST405 CREC clone, which exhibits both enhanced virulence and extensive drug resistance. These results highlight the urgent need for stringent surveillance and targeted interventions to curb its further dissemination and prevent potential outbreaks.

31 Dec 2025·Emerging Microbes & Infections

Scarless excision of an insertion sequence in the OmpK36 promoter restores meropenem susceptibility in a non-carbapenemase-producing Klebsiella pneumoniae

Article

Author: Gong, Yuanzhi ; Yuan, Yinghua ; Zhu, Yunlou ; Wang, Sheng ; Du, Yingying ; Liu, Tong ; Liu, Yuhao ; Hao, Min

Carbapenem-resistant Klebsiella pneumoniae (CRKP) poses a significant global health challenge due to its limited treatment options and high mortality rates. Meanwhile, the prevalence of non-carbapenemase-producing CRKP (NC-CRKP) strains is increasing, but their resistance mechanisms remain less understood compared to those of carbapenemase-producing CRKP (CP-CRKP). In this study, KP-469, an NC-CRKP strain, was found to lack the major porins OmpK35 and Ompk36 but possessed OmpK37, coexisting with ESBL resistance genes CTX-M and SHV. Membrane porin coding sequence alignment revealed a minor deletion in Ompk35 and a 768 bp insertion sequence in the promoter region (IS-PR) of Ompk36, located between the -10 region and the ribosome-binding site (RBS). In the KO-469 strain with scarless excision of IS-PR and the constructed pHSG396-promoter-Ompk36 strain that incorporated wild-type Ompk36 promoter into KP-469, the transcription levels of Ompk36 were significantly higher than that in KP-469 strain, and His-tag antibody quantification further confirmed the regular expression of Ompk36 in KO-469. These results demonstrated that IS-PR markedly reduced the transcriptional and translational efficiency of Ompk36 in the KP-469 strain, leading to decreased permeability to meropenem. Moreover, the restored susceptibility to meropenem in the KO-469 strain was validated by in vitro antimicrobial susceptibility tests and an in vivo intraperitoneal infection model constructed in neutrophil-depleted mice. The novel carbapenem resistance mechanism of NC-CRKP caused by the insertion sequence in the OmpK36 promoter will facilitate the development of antibacterial regimens for treating NC-CRKP infections.

112

News (Medical) associated with Meropenem

07 Aug 2025

·pipelinereview.com

CorMedix to acquire Melinta Therapeutics, Creating Diversified Specialty Company With Strong Presence in Acute Care Settings

BERKELEY HEIGHTS, NJ, USA I August 07, 2025 I CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, and Melinta Therapeutics LLC (“Melinta”), a private commercial-stage company providing innovative therapies for acute and life-threatening illnesses, today announced a definitive agreement for CorMedix to acquire Melinta. The selling shareholders will receive $300 million in total consideration at closing, including $40 million of CorMedix equity, and will be eligible to receive a regulatory milestone of up to $25 million and royalties on net sales of MINOCIN ® and REZZAYO™. The proposed acquisition will expand CorMedix’s team and commercial platform, and increase the commercial portfolio with six marketed, highly differentiated, hospital- and clinic-focused infectious disease products, including REZZAYO™ (rezafungin for injection), MINOCIN ® (minocycline) for Injection, VABOMERE ® (meropenem and vaborbactam), KIMYRSA ® (oritavancin), ORBACTIV™ (oritavancin), BAXDELA ® (delafloxacin), and an additional well-established cardiovascular product, TOPROL-XL ® (metoprolol succinate). REZZAYO™ is currently approved for the treatment of candidemia and invasive candidiasis in adults, with an ongoing Phase III study for the prophylaxis of invasive fungal infections in adult patients undergoing allogeneic blood and marrow transplantation. The completion of the Phase III study for REZZAYO™ is expected in 1H 2026. “This acquisition is a transformational step in the evolution of CorMedix, providing an attractive revenue base of highly synergistic assets, as well as multiple opportunities to drive future growth. We are excited to acquire Melinta, which enables us to expand our product portfolio in the hospital space while delivering therapies to patients with high unmet need,” said Joseph Todisco, CEO of CorMedix Inc. “I would like to congratulate Christine Ann Miller, Melinta Therapeutics President & CEO, on building a high-performing organization. The combination with Melinta creates a formidable and diversified specialty platform with a deep and experienced team in the hospital acute care and infectious disease arena. This transaction reflects the type of high-impact, cash-flow generating opportunities we are targeting and strengthens our position to further expand, as we strive to create shareholder value through both organic growth and additional acquisitions in the future.” “The synergistic combination of Melinta and CorMedix represents an exciting new chapter in our company’s evolution,” said Christine Ann Miller, President and CEO of Melinta Therapeutics. “Over the past five years, we have built a robust commercial infrastructure with a high-performing team, deep expertise, and relationships within the hospital and acute care ecosystem, while achieving significant revenue growth and sustained profitability. CorMedix recognizes not just our innovative therapies, but the exceptional capabilities of our organization. I’m confident that Melinta’s commercial excellence and proven track record will augment CorMedix’s team and track record of operational execution and success, to create an even stronger platform for future growth.” Strategic and Financial Benefits Terms and Financing Under the terms of the agreement, which has been approved by the CorMedix and Melinta Board of Directors respectively, CorMedix will pay $300 million in upfront consideration, comprised of $260 million in cash and $40 million in CorMedix equity issued to Melinta shareholders of Deerfield Management Company, L.P. (“Deerfield”). The cash consideration will be funded by a combination of CorMedix’s existing cash on hand and the proceeds of a $150 million convertible debt financing with high quality healthcare focused institutional investors, including Deerfield, the terms of which will be described in a Current Report on Form 8-K to be filed by the Company today. The agreement contains an additional regulatory milestone of up to $25 million (payable in cash or shares at CorMedix’s election) for the FDA approval of the expanded indication of REZZAYO™ for prophylaxis of invasive fungal infections in adults undergoing allogeneic blood and marrow transplantation, if this milestone event is achieved by June 30, 2029. Furthermore, the agreement includes tiered royalties on REZZAYO™ U.S. net sales and low-single-digit royalties on MINOCIN ® U.S. net sales. The transaction is subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the ‘HSR Act’). The Company expects the transaction to close as early as September 1, 2025. Full Year Financial Guidance Advisors Moelis & Company LLC is acting as exclusive financial advisor for CorMedix in connection with the acquisition of Melinta and sole placement agent for convertible debt financing. Willkie Farr & Gallagher LLP is acting as legal advisor to CorMedix in connection with the acquisition of Melinta and the convertible debt financing. RBC Capital Markets is acting as a financial advisor to CorMedix in connection with the convertible debt financing. Goodwin Procter LLP is acting as a legal advisor to Moelis & Company LLC for the convertible debt financing. Conference Call and Webcast Information Management will host a conference call and a live webcast today, August 7, 2025, at 8:30 a.m. ET, to discuss the transaction and CorMedix’s second quarter 2025 financial results. The conference call can be accessed by dialing 1-844-676-2922 from the United States or 1-412-634-6840 internationally. The live webcast will be accessible in the “ Presentations & Events ” section of the CorMedix Investor Relations website or using the following Webcast Link . About CorMedix CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath ® (taurolidine and heparin) which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath ® in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix is commencing clinical studies in Total Parenteral Nutrition and Pediatric patient populations in 2025 and also intends to develop DefenCath ® as a catheter lock solution for use in other patient populations. For more information visit: www.cormedix.com . About Melinta Melinta Therapeutics is a biopharmaceutical company dedicated to providing innovative therapies to people impacted by acute and life-threatening illnesses. We focus our expanding portfolio on serving patients with an unmet need because that’s how we make the most meaningful impact. At Melinta, we’re visionaries dedicated to innovation while staying grounded in what matters most: patients. Our portfolio currently includes seven commercial-stage products: MINOCIN ® (minocycline), REZZAYO™ (rezafungin), VABOMERE ® (meropenem and vaborbactam), ORBACTIV™ (oritavancin), BAXDELA ® (delafloxacin), KIMYRSA ® (oritavancin), and TOPROL-XL ® (metoprolol succinate). For more information about Melinta Therapeutics, our commitment to patients, and to learn about our portfolio of therapies, visit www.melinta.com . SOURCE: CorMedix

Drug ApprovalPhase 3AcquisitionLicense out/in

06 Jun 2025

·pharma.economictimes.indiatimes.com

API prices fall sharply, easing pressure on India's pharmaceutical industry

New Delhi: Prices of active pharmaceutical ingredients (API) used for manufacturing drugs are seeing a significant drop, bringing relief to India's pharmaceutical industry. The pharma industry depends largely on China for sourcing APIs, intermediates and bulk drugs. API prices had shot up during the Covid period and stayed elevated until last year. The situation has now started to change, reducing raw material cost and boosting profit margins for pharma companies. For instance, the price of paracetamol API has dropped from ₹900 per kg during the pandemic and ₹600 immediately after to ₹250 now, market sources told ET. The API for antibiotic meropenem has become cheaper at ₹45,000 per kg compared with ₹75,000. "Prices of APIs have gone down significantly. It's largely due to over-capacity. We are seeing a huge impact on the prices of antibiotics, steroids, hormones, statins, among others," said Mehul Shah, who tracks the Chinese pharmaceutical industry. Shah expects this trend to continue through this year. An industry expert said the prices have come down because of the aggressive strategy of Chinese suppliers to maintain market dominance. "This aggressive pricing has made Chinese APIs more attractive to Indian pharmaceutical companies, leading to increased imports when prices are low," he said on the condition of anonymity. Dinesh Dua, former chairman of the Pharmaceutical Export Promotion Council, said there were several factors that led to the price decline. "While China scaled up significantly after Covid-19, the demand for APIs has gone down too as India has taken steps to become self-reliant," he said. "India's government has implemented the production-linked incentive scheme to boost domestic API production. As a result, companies like Aurobindo Pharma and Torrent Pharmaceuticals have initiated local production of APIs such as penicillin-G. This increased domestic output has contributed to a surplus in supply, exerting downward pressure on prices." Dua said a decline in the prices of raw materials, such as acetic acid and para-aminophenol, essential for API production, has also contributed to lower costs. "Additionally, easing geopolitical tensions and improved logistics have reduced freight charges, further decreasing the overall cost of API," he added. According to industry experts, a gradual return of demand to pre-pandemic levels has also contributed to this situation. By Teena Thacker ,

10 Apr 2025

·pipelinereview.com

Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Interim blinded safety and pharmacokinetic data to be presented at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) ROCKVILLE, MD, USA I April 10, 2025 I Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the presentation of the previously disclosed blinded safety and pharmacokinetic (PK) data from the ongoing Phase 1b/2a randomized, double-blinded, placebo-controlled clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant (HCT) recipients for the prevention of acute graft-versus-host-disease (aGVHD). These data will be featured in an ePoster Flash Session oral presentation at the Congress of the European Society of  Clinical Microbiology and Infectious Diseases (ESCMID Global), taking place in Vienna, Austria from April 11-15, 2025. Details on ePoster number E0145 can be found below. About the Phase 1b/2a Clinical Trial The ongoing randomized, double-blinded, placebo-controlled Phase 1b/2a clinical trial is being conducted at Washington University School of Medicine in St. Louis. The trial is designed to evaluate the safety, tolerability, and potential absorption of oral SYN-004 (150 mg q.i.d. for a maximum of 28 days) into the systemic circulation of allogeneic HCT recipients who receive an IV antibiotic to treat fever. To mitigate risk, Cohort 1 of the study administered meropenem as the study-assigned antibiotic. Meropenem is a carbapenem antibiotic that is not metabolized by SYN-004. Patients in Cohort 2 were administered piperacillin/tazobactam as the study-assigned antibiotic and patients in Cohort 3 will receive cefepime. Piperacillin and cefepime can be metabolized by SYN-004. The trial is also designed to evaluate potential protective effects of SYN-004 on the gut microbiome as well as generate preliminary information on potential therapeutic benefits and patient outcomes of SYN-004 in allogeneic HCT recipients. The trial is expected to enroll up to 36 participants with three sequential cohorts, each evaluating a different study-assigned IV beta-lactam antibiotic. Safety and pharmacokinetic data for each cohort is reviewed by an independent Data and Safety Monitoring Committee that makes a recommendation on whether to proceed to the next IV beta-lactam antibiotic. More information on the study is available here ( NCT04692181 ). About SYN-004 (ribaxamase) SYN-004 (ribaxamase) is an oral prophylactic therapy designed to degrade certain IV beta-lactam antibiotics within the GI tract and maintain the natural balance of the gut microbiome for the prevention of Clostridioides difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR) and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients. Allogeneic HCT recipients routinely receive long courses of IV beta-lactam antibiotics to treat infection following conditioning therapy. Antibiotic-mediated damage of the gut microbiome in allogeneic HCT recipients may lead to adverse outcomes including CDI, VRE colonization and potentially fatal bacteremia and aGVHD. A previously completed placebo-controlled Phase 2b clinical trial of 412 patients demonstrated SYN-004 protected the gut microbiome from antibiotic-mediated dysbiosis. Patients who received SYN-004 also demonstrated significantly better maintenance and recovery of the gut microbiome as well as lower incidences of new colonization by opportunistic and potentially pathogenic microorganisms such as VRE. About Theriva™ Biologics, Inc. Theriva™ Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company’s subsidiary Theriva Biologics, S.L. , has been developing a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient’s immune system. The Company’s lead clinical-stage candidates are: (1) VCN-01 (zabilugene almadenorepvec), an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment; (2) SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci) and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients); and (3) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases. For more information, please visit Theriva Biologics’ website at www.therivabio.com . SOURCE: Theriva Biologics

Clinical ResultPhase 2ImmunotherapyCell Therapy

100 Deals associated with Meropenem

External Link

KEGG	Wiki	ATC	Drug Bank
D08185	Meropenem	J01DH02	DB00760

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Complicated intra-abdominal infection	United States	B. Braun Medical, Inc.	30 Apr 2015
(non-specific) purulent meningitis	Japan	Sumitomo Pharma Co., Ltd.	23 Apr 2004
Bacterial Infections	China	Zhejiang Hisun Pharmaceutical Co., Ltd.	01 Jan 1998
Community acquired respiratory tract infection	Australia	Pfizer Australia Pty Ltd.	25 Jul 1996
Complicated urinary tract infection	Australia	Pfizer Australia Pty Ltd.	25 Jul 1996
Febrile Neutropenia	Australia	Pfizer Australia Pty Ltd.	25 Jul 1996
Gynecological infection	Australia	Pfizer Australia Pty Ltd.	25 Jul 1996
Hospital-acquired pneumonia	Australia	Pfizer Australia Pty Ltd.	25 Jul 1996
Meningitis	Australia	Pfizer Australia Pty Ltd.	25 Jul 1996
Intraabdominal Infections	United States	Pfizer Inc.	21 Jun 1996
Meningitis, Bacterial	United States	Pfizer Inc.	21 Jun 1996
Skin and skin structure infections	United States	Pfizer Inc.	21 Jun 1996
Adnexitis	Japan	Sumitomo Pharma Co., Ltd.	30 Jun 1995
Arthritis	Japan	Sumitomo Pharma Co., Ltd.	30 Jun 1995
Cholangitis	Japan	Sumitomo Pharma Co., Ltd.	30 Jun 1995
Cholecystitis	Japan	Sumitomo Pharma Co., Ltd.	30 Jun 1995
Complicated skin and skin structure infection	Japan	Sumitomo Pharma Co., Ltd.	30 Jun 1995
Cystitis	Japan	Sumitomo Pharma Co., Ltd.	30 Jun 1995
Endophthalmitis	Japan	Sumitomo Pharma Co., Ltd.	30 Jun 1995
Intrauterine infection	Japan	Sumitomo Pharma Co., Ltd.	30 Jun 1995

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pneumonia, Ventilator-Associated	Phase 3	-	Melinta Therapeutics, Inc.	01 Aug 2018
Abscess	Phase 3	-	Pfizer Inc.	01 Feb 2001
Cellulitis	Phase 3	-	Pfizer Inc.	01 Feb 2001
Pneumonia	Preclinical	Sweden	Double Bond Pharmaceutical International AB	24 Sep 2021
Infectious Diseases	Preclinical	United States	Matinas BioPharma Holdings, Inc.	31 Dec 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05392634 (Pubmed \| Arab J Urol)	Phase 3	-	92	Standard 24-h AP regimen	fbbtudrikq(ojkjzvdeoq) = karvplvsfg sqfzarjchm (nlhxwurxco ) View more	Positive	01 Oct 2024
				Prolonged meropenem AP 120-h	fbbtudrikq(ojkjzvdeoq) = kaxijvqrwn sqfzarjchm (nlhxwurxco ) View more
NCT05102162 (CTgov)	Phase 4	Pneumonia	35	Meropenem+Piperacillin/Tazobactam+Cefepime (Continuous Antibiotic Dose Over 24 Hours Arm)	uilpsgzqgb = keiyppamez oabmjgyifc (gzkropmqoe, bflpriwttu - cybkxjyuag) View more	-	12 Dec 2023
				Meropenem+Piperacillin/Tazobactam+Cefepime (Intermittent Antibiotic Dose Over 30 Minutes)	uilpsgzqgb = syymhgoqcz oabmjgyifc (gzkropmqoe, zrjttkhfjs - snsnrabafs) View more
FDA Manual	Not Applicable	Meningitis, Bacterial	446	Meropenem 40 mg/kg	ysggwaupyt(nmaypsibfl) = Most common adverse reactions (incidence ≥ 1%) are diarrhea, rash (mostly diaper area moniliasis), oral moniliasis, and glossitis. ymohugosec (itsipwyocu )	Positive	26 Jul 2023
				cefotaxime or ceftriaxone
NCT03174184 (COMRADE, CTgov)	Phase 2	Pulmonary Tuberculosis	112	MEROPENEM 2 grams TID+Rifampin+Amoxicillin/Clavulanate Potassium 500 MG-125 MG Oral Tablet (Rifampin Resistant A)	suqwqrnibx(yjllreehoi) = zuddrfhdwx iysitxkcxq (dowbbtzqrv, qyscnlnerz - dqqqkpjmwq) View more	-	19 Jul 2023
				MEROPENEM 2 grams TID+Amoxicillin/Clavulanate Potassium 500 MG-125 MG Oral Tablet (Rifampin Resistant B)	suqwqrnibx(yjllreehoi) = odwzbfcbnm iysitxkcxq (dowbbtzqrv, yrjgkjsyyy - npjxhhrxaq) View more
NCT03174184 (COMRADE, Pubmed)	Phase 2	Tuberculosis Second line	112	Meropenem 2 grams 8 hourly	qdnngekgmo(ncklrypmzn) = Tolerability of intravenous meropenem, with amoxicillin/clavulanate, though, was poor at all doses, calling into question the utility of this drug in second-line regimens. qxsedjpsah (bztwvpfetx )	Negative	08 Mar 2022
				Meropenem 2 grams 8 hourly plus rifampin 20 mg/kg once daily
NCT01597973 (OVERCOME, CTgov)	Phase 3	Pneumonia \| Sepsis \| Hospital-acquired pneumonia	467	colistin and placebo	wwddnqavjq = eovhvkwntn gkdjqbziro (oegotasami, zgncutxiwg - wsytsoowcv) View more	-	30 Nov 2021
NCT02437045 (MERINO-2, Pubmed \| Open Forum Infect Dis)	Phase 4	Sepsis	-	Piperacillin-tazobactam 4.5 g	idanbdfoxe(altwitthed) = ivwtilutxe pxtjqnahxe (xmctjfixhy )	-	01 Aug 2021
				Meropenem 1 g	duyykugsye(mddzjdjlwl) = mdctpmwbav uhwvmyjizr (mgzflhkwxp )
NCT05578586 (Pubmed \| J Intensive Care Med)	Not Applicable	Critical Illness	-	Extended Infusion Meropenem (EIM)	fynyxnnxid(xidcxyoqcq) = ghubhckxxd rtsilfyvgy (jtubycfond ) View more	Positive	01 Aug 2020
				Intermittent Infusion Meropenem (IIM)	fynyxnnxid(xidcxyoqcq) = exlafuwdwg rtsilfyvgy (jtubycfond ) View more
NCT01551394 (NeoMero1, Pubmed) Manual	Phase 3	Neonatal Sepsis	272	Meropenem (Meropenem arm)	yvpblpgazv(yrflvhnkbo) = xqszcdcfjb vmhwpxysam (yngdmqyjei ) View more	Non-superior	04 Mar 2020
				ampicillin+gentamicin+cefotaxime (SOC arm)	yvpblpgazv(yrflvhnkbo) = rfriqvkyyg vmhwpxysam (yngdmqyjei ) View more
NCT01944319 (CTgov)	Phase 4	Lower Respiratory Tract Infections	79	Routine meropenem therapy (Control Group)	lxwtaneayv = vmjrnjxzaz wfqwftaflv (lzmmgrawso, bjjxqfyvvv - oownonijkk) View more	-	25 Feb 2016
				Meropenem therapy based on a PPK and PD model (Study Group)	lxwtaneayv = hjtsxiwcgr wfqwftaflv (lzmmgrawso, kzjhnofekx - wkqwakkuta) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Meropenem

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation